Merck Charter Oak Partner

Connecticut Oncology Association

Home

About Us

Officers

Contact Us

Events

Corporate Partners

Membership

Member Application

Resources

Members Only

Corporate Sites

https://www.merck.com/index.html

Oncology Products and Prescribing Information site

Contact in CT:

Mark Montello

Medicare Account Executive

603-321-1145

Mark.Montello@merck.com

Important News and Information

FDA Approves Expanded Indication for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer 12/15/2023

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation 06/24/2020

FDA Approves Second Biomarker-Based Indication for Merck’s KEYTRUDA® (pembrolizumab), Regardless of Tumor Type

06/17/2020

Connecticut Oncology Association (CtOA)

c/o Dawn Holcombe

33 Woodmar Circle
South Windsor, CT 06074
(860) 305-4510

Website design by Sister Webs Design Studio, where 5% of profits are donated to women's cancer funds

Powered by Wild Apricot Membership Software